From: Role of fecal calprotectin as a hypoxic intestinal damage biomarker in COVID-19 patients
Characteristics | Total (n = 44) | FC-negative (< 50) (n = 26) | FC-positive (≥ 50) (n = 18) | P-value |
---|---|---|---|---|
Gender | Â | Â | Â | 0.241 |
 Male | 23 (52.3%) | 16 (61.5%) | 7 (38.9%) |  |
 Female | 21 (47.7%) | 10 (38.5%) | 11 (61.1%) |  |
Age (years) | 48.7 ± 14.2 | 47.8 ± 13.9 | 49.9 ± 14.8 | 0.573 |
 18–59 | 32 (72.7%) | 19 (73.1%) | 13 (72.2%) |  |
  ≥ 60 | 12 (27.3%) | 7 (26.9%) | 5 (27.8%) |  |
Any comorbidity* | 26 (59.1%) | 16 (61.5%) | 10 (55.6%) | 0.932 |
Hypertension | 18 (40.9%) | 12 (46.2%) | 6 (33.3%) | 0.590 |
Diabetes Mellitus | 22 (50%) | 13 (50%) | 9 (50%) | 1.000 |
Respiratory symptoms* | ||||
 Fever | 31 (70.5%) | 18 (69.2%) | 13 (72.2%) | 1.000 |
 Cough | 33 (75%) | 19 (73.1%) | 14 (77.8%) | 1.000 |
 Dyspnea | 30 (68.2%) | 18 (69.2%) | 12 (66.7%) | 1.000 |
 Anosmia | 4 (9.1%) | 3 (11.5%) | 1 (5.6%) | 0.634 |
Gastrointestinal symptoms* | ||||
 Nausea | 17 (38.6%) | 1 (3.8%) | 16 (88.9%) |  < 0.001 |
 Vomiting | 13 (29.5%) | 0 (0%) | 13 (72.2%) |  < 0.001 |
 Diarrhea | 14 (31.8%) | 1 (3.8%) | 13 (72.2%) |  < 0.001 |
 Abdominal pain | 5 (11.4%) | 1 (3.8%) | 4 (22.2%) | 0.142 |
 Decreased appetite | 28 (63.6%) | 13 (50%) | 15 (83.3%) | 0.052 |
Laboratory findings | ||||
 Leukocyte (/µL) | 10 113.4 ± 4471.21 | 9465.8 ± 2802.4 | 11 048.9 ± 6119.6 | 0.775 |
 Thrombocyte (/µL) | 335 227.3 ± 135 671.3 | 345 884.6 ± 135 865.9 | 319 833.3 ± 137 793.6 | 0.537 |
 NLR | 7.5 ± 8.2 | 6.3 ± 3.3 | 9.33 ± 12.12 | 0.567 |
 Ferritin (ng/ml) | 761.3 ± 664.3 | 774.5 ± 669.6 | 739.8 ± 676.8 | 0.736 |
 D-Dimer (ng/ml) | 4469.4 ± 8327.3 | 4536.7 ± 8048.8 | 4372.2 ± 8950.5 | 0.384 |
 CRP (mg/L) | 1.9 ± 2.4 | 1.6 ± 1.7 | 2.6 ± 3.2 | 0.952 |